SAN FRANCISCO--(BUSINESS WIRE)--Solazyme, Inc. (NASDAQ:SZYM), a renewable oil and ingredients company, is pleased to announce that the US Food and Drug Administration (FDA) has issued a favorable response to Solazyme’s notification concluding that Whole Algal Protein is Generally Recognized as Safe (GRAS) as an ingredient in food and beverage products. This No Questions letter will further pave the way for mainstream adoption of this new source of vegan protein enabling the creation of new products that meet consumer demand for healthy, sustainable ingredients.
Commercialized under the brand AlgaVia™ Microalgae Food Ingredients, Solazyme uses microalgae, a nutrient-filled cell that is one of earth’s first foods, to produce its nutrient-rich ingredients, including AlgaVia™ Whole Algal Protein and AlgaVia™ Whole Algal Flour. AlgaVia™ Whole Algal Flour received a GRAS No Questions letter from the FDA in June 2013. AlgaVia™ Whole Algal Protein and AlgaVia™ Whole Algal Flour are the first-ever microalgae-based food ingredients of their kind to be GRAS.
“Solazyme continues to build momentum in our microalgae food ingredient platform with this latest No Questions letter, an important milestone for the AlgaVia™ product line,” said Mark Brooks, SVP, Solazyme Food Ingredients. “AlgaVia™ will help further Solazyme’s commitment to delivering healthy products that are better for both people and the planet, and to helping food companies create more nutritious, great-tasting foods made with these sustainable microalgae-based ingredients.”
AlgaVia™ Whole Algal Protein is a vegan-friendly, gluten-free product that contains a rich collection of fiber, lipids and micronutrients such as lutein and zeaxanthin. Because of its unique whole cell nature, the protein fortifies in challenging applications such as low pH beverages, dressings and crackers. AlgaVia™ Whole Algal Flour is a trans-fat- and cholesterol-free lipid powder that enables the creation of healthier products with satisfying taste and texture. This new healthier fat source enables the reduction or replacement of dairy fats, oil and egg yolks.
These two AlgaVia™ microalgae food ingredients are GRAS for use in a vast number of food and beverage applications, including baked goods and mixes, breakfast cereals, meal replacements, cheeses, milk products, dairy and nondairy products, frozen dairy, egg products, sauces, snack foods, salad dressings, juices, and more.
About Solazyme, Inc.
Solazyme, Inc. (Nasdaq:SZYM) is the leading microalgae innovator that delivers first-of-a-kind, high-performance oils and ingredients that are better for people and better for the planet. Starting with microalgae, the world’s original oil producer, Solazyme creates new, sustainable, high-performance products. These include renewable oils and powerhouse ingredients that serve as the foundation for healthier foods; better home, personal care and industrial products; and more sustainable fuels. Headquartered in South San Francisco, Solazyme’s mission is to solve some of the world’s biggest problems with one of its smallest and most ancient life forms: microalgae.
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: its commercialization and production plans; meeting commercialization and technology targets; market acceptance of its products; and Solazyme’s ability to maintain its relationships with its partners. When used in this press release, the words “will”, “can”, “anticipate”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies; its limited experience in constructing, ramping up and operating commercial manufacturing facilities; its ability to sell its products at a profit; delays related to start-up and ramp-up of production facilities; its ability to manage operational costs at production facilities; its ability to enter into and maintain strategic collaborations; successful product trials by its customers and market acceptance of its products by end-users; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.